Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience

[1] El-Serag HB(2007)Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557-2576

[2] Rudolph KL(2001)Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421-430

[3] Bruix J(2002)Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 519-524

[4] Sherman M(2003)Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 429-442

[5] Llovet JM(2002)Arterial embolization or chemoembolization verses systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial Lancet 359 1734-1739

[6] Bruix J(2009)Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 20 S219-S226

[7] Llovet JM(2008)Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan Cardiovasc Intervent Radiol 31 756-761

[8] Llovet JM(2002)Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 47-54

[9] Bruix J(1994)Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study Cancer 74 2449-2453

[10] Llovet JM(1992)Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan Cancer Chemother Pharmacol 31 S1-S6

[1] El-Serag HB(2007)Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557-2576

[2] Rudolph KL(2001)Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421-430

[3] Bruix J(2002)Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 519-524

[4] Sherman M(2003)Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 429-442

[5] Llovet JM(2002)Arterial embolization or chemoembolization verses systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial Lancet 359 1734-1739

[6] Bruix J(2009)Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 20 S219-S226

[7] Llovet JM(2008)Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan Cardiovasc Intervent Radiol 31 756-761

[8] Llovet JM(2002)Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 47-54

[9] Bruix J(1994)Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study Cancer 74 2449-2453

[10] Llovet JM(1992)Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan Cancer Chemother Pharmacol 31 S1-S6